{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:48Z","timestamp":1791484368143,"version":"4.3.4"},"reference-count":180,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNPPY"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1093\/ijnp\/pyw030","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T00:19:09Z","timestamp":1459642749000},"page":"pyw030","source":"Crossref","is-referenced-by-count":54,"title":["Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications"],"prefix":"10.1093","volume":"19","author":[{"given":"Pim R. A.","family":"Heckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies A.","family":"van Duinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva P. P.","family":"Bollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"Wennogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Blokland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Prickaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,4,2]]},"reference":[{"key":"2016102519281274000_19.10.pyw030.1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(90)90107-L"},{"key":"2016102519281274000_19.10.pyw030.2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0079-6123(08)62678-3","article-title":"Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, \u201cprefrontal\u201d and \u201climbic\u201d functions","volume":"85","author":"Alexander","year":"1990","journal-title":"Prog Brain Res"},{"key":"2016102519281274000_19.10.pyw030.3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.09.030186.002041"},{"key":"2016102519281274000_19.10.pyw030.4","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bht195"},{"key":"2016102519281274000_19.10.pyw030.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.01.020"},{"key":"2016102519281274000_19.10.pyw030.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.01.006"},{"key":"2016102519281274000_19.10.pyw030.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20296"},{"key":"2016102519281274000_19.10.pyw030.8","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2153"},{"key":"2016102519281274000_19.10.pyw030.9","doi-asserted-by":"publisher","DOI":"10.1076\/jhin.11.3.265.10391"},{"key":"2016102519281274000_19.10.pyw030.10","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002642"},{"key":"2016102519281274000_19.10.pyw030.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2007.08.002"},{"key":"2016102519281274000_19.10.pyw030.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427396"},{"key":"2016102519281274000_19.10.pyw030.13","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.5"},{"key":"2016102519281274000_19.10.pyw030.14","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"2016102519281274000_19.10.pyw030.15","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0782-06.2006"},{"key":"2016102519281274000_19.10.pyw030.16","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1523\/JNEUROSCI.20-22-08443.2000","article-title":"Dopamine and cAMP-regulated phosphoprotein 32kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity","volume":"20","author":"Calabresi","year":"2000","journal-title":"J Neurosci"},{"key":"2016102519281274000_19.10.pyw030.17","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3743"},{"key":"2016102519281274000_19.10.pyw030.18","doi-asserted-by":"publisher","DOI":"10.1038\/90458"},{"key":"2016102519281274000_19.10.pyw030.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6989(83)80017-4"},{"key":"2016102519281274000_19.10.pyw030.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-0618(01)00115-6"},{"key":"2016102519281274000_19.10.pyw030.21","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.043968"},{"key":"2016102519281274000_19.10.pyw030.22","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.0.CO;2-R"},{"key":"2016102519281274000_19.10.pyw030.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.07.014"},{"key":"2016102519281274000_19.10.pyw030.24","doi-asserted-by":"publisher","DOI":"10.1038\/nature11846"},{"key":"2016102519281274000_19.10.pyw030.25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00878.x"},{"key":"2016102519281274000_19.10.pyw030.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.09.006"},{"key":"2016102519281274000_19.10.pyw030.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2008.02.010"},{"key":"2016102519281274000_19.10.pyw030.28","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0920-9964(12)70783-1","article-title":"Poster #212 results of a phase 2a proof-of-concept trial with a PDE10A Inhibitor in the treatment of acute exacerbation of schizophrenia","volume":"136","author":"DeMartinis","year":"2012","journal-title":"Schizophr Res"},{"key":"2016102519281274000_19.10.pyw030.29","doi-asserted-by":"publisher","DOI":"10.1038\/nature03966"},{"key":"2016102519281274000_19.10.pyw030.30","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150605110941"},{"key":"2016102519281274000_19.10.pyw030.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-183X.2006.00209.x"},{"key":"2016102519281274000_19.10.pyw030.32","doi-asserted-by":"publisher","DOI":"10.1080\/07853890802441169"},{"key":"2016102519281274000_19.10.pyw030.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.01.029"},{"key":"2016102519281274000_19.10.pyw030.34","doi-asserted-by":"publisher","DOI":"10.1097\/YPG.0b013e3283060fb8"},{"key":"2016102519281274000_19.10.pyw030.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.02.1055"},{"key":"2016102519281274000_19.10.pyw030.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(99)00015-7"},{"key":"2016102519281274000_19.10.pyw030.37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnana.2011.00036","article-title":"Adenosine A2A receptors and A2A receptor heteromers as key players in striatal function","volume":"5","author":"Ferre","year":"2011","journal-title":"Front Neuroanat"},{"key":"2016102519281274000_19.10.pyw030.38","doi-asserted-by":"publisher","DOI":"10.1159\/000091806"},{"key":"2016102519281274000_19.10.pyw030.39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/1381612820666140826113957","article-title":"Phosphodiesterases as therapeutic targets for Huntington\u2019s disease","volume":"21","author":"Fusco","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2016102519281274000_19.10.pyw030.40","doi-asserted-by":"crossref","unstructured":"Gentzel RC Toolan D Roberts R Koser AJ Kandebo M Hershey J Renger JJ Uslaner J Smith SM (2015) The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. Neuropharmacology.","DOI":"10.1016\/j.neuropharm.2015.05.024"},{"key":"2016102519281274000_19.10.pyw030.41","doi-asserted-by":"publisher","DOI":"10.1126\/science.2147780"},{"key":"2016102519281274000_19.10.pyw030.42","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-061010-113641"},{"key":"2016102519281274000_19.10.pyw030.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013417"},{"key":"2016102519281274000_19.10.pyw030.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2009.06649.x"},{"key":"2016102519281274000_19.10.pyw030.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.02.014"},{"key":"2016102519281274000_19.10.pyw030.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06310.x"},{"key":"2016102519281274000_19.10.pyw030.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06387.x"},{"key":"2016102519281274000_19.10.pyw030.48","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.155994"},{"key":"2016102519281274000_19.10.pyw030.49","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013205230142"},{"key":"2016102519281274000_19.10.pyw030.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80798-9"},{"key":"2016102519281274000_19.10.pyw030.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3371-7"},{"key":"2016102519281274000_19.10.pyw030.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-011-1120-8"},{"key":"2016102519281274000_19.10.pyw030.53","doi-asserted-by":"crossref","unstructured":"Gurney ME Burgin AB Magnusson OT Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol:167\u2013192.","DOI":"10.1007\/978-3-642-17969-3_7"},{"key":"2016102519281274000_19.10.pyw030.54","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.146"},{"key":"2016102519281274000_19.10.pyw030.55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2009.06709.x"},{"key":"2016102519281274000_19.10.pyw030.56","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001558"},{"key":"2016102519281274000_19.10.pyw030.57","first-page":"744","article-title":"PDEs as drug targets for CNS immune disorders","volume":"9","author":"Hebb","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"2016102519281274000_19.10.pyw030.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2003.11.009"},{"key":"2016102519281274000_19.10.pyw030.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2014.10.011"},{"key":"2016102519281274000_19.10.pyw030.60","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(94)00012-R"},{"key":"2016102519281274000_19.10.pyw030.61","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021698"},{"key":"2016102519281274000_19.10.pyw030.62","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000261934.56938.38"},{"key":"2016102519281274000_19.10.pyw030.63","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(97)01050-5"},{"key":"2016102519281274000_19.10.pyw030.64","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7483"},{"key":"2016102519281274000_19.10.pyw030.65","first-page":"217","article-title":"Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+","volume":"46","author":"Hulley","year":"1995","journal-title":"J Neural Transm Suppl"},{"key":"2016102519281274000_19.10.pyw030.66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1995.tb01041.x"},{"key":"2016102519281274000_19.10.pyw030.67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0169-328X(96)00062-9","article-title":"The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression","volume":"41","author":"Hung","year":"1996","journal-title":"Brain Res Mol Brain Res"},{"key":"2016102519281274000_19.10.pyw030.68","doi-asserted-by":"publisher","DOI":"10.1038\/350230a0"},{"key":"2016102519281274000_19.10.pyw030.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00969-7"},{"key":"2016102519281274000_19.10.pyw030.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80120-8"},{"key":"2016102519281274000_19.10.pyw030.71","unstructured":"Intra-Cellular Therapies (2014) Products and technology: PDE inhibitor platform. Available at http:\/\/www.intracellulartherapies.com\/products-technology\/pde-inhibitor-platform.html."},{"key":"2016102519281274000_19.10.pyw030.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2006.07.005"},{"key":"2016102519281274000_19.10.pyw030.73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.295"},{"key":"2016102519281274000_19.10.pyw030.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.07.021"},{"key":"2016102519281274000_19.10.pyw030.75","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795049624"},{"key":"2016102519281274000_19.10.pyw030.76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01729.x"},{"key":"2016102519281274000_19.10.pyw030.77","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.173294"},{"key":"2016102519281274000_19.10.pyw030.78","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308471200"},{"key":"2016102519281274000_19.10.pyw030.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2010.07.002"},{"key":"2016102519281274000_19.10.pyw030.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2011.05.002"},{"key":"2016102519281274000_19.10.pyw030.81","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1996.67020443.x"},{"key":"2016102519281274000_19.10.pyw030.82","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2436-8"},{"key":"2016102519281274000_19.10.pyw030.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.05.004"},{"key":"2016102519281274000_19.10.pyw030.84","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204832200"},{"key":"2016102519281274000_19.10.pyw030.85","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1523\/JNEUROSCI.15-12-07810.1995","article-title":"Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson\u2019s disease","volume":"15","author":"Levivier","year":"1995","journal-title":"J Neurosci"},{"key":"2016102519281274000_19.10.pyw030.86","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01751"},{"key":"2016102519281274000_19.10.pyw030.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.10.037"},{"key":"2016102519281274000_19.10.pyw030.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.12.008"},{"key":"2016102519281274000_19.10.pyw030.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2007.08.018"},{"key":"2016102519281274000_19.10.pyw030.90","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","article-title":"Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus","volume":"19","author":"Lu","year":"1999","journal-title":"J Neurosci"},{"key":"2016102519281274000_19.10.pyw030.91","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.9.1259"},{"key":"2016102519281274000_19.10.pyw030.92","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.3"},{"key":"2016102519281274000_19.10.pyw030.93","doi-asserted-by":"publisher","DOI":"10.1038\/ng882"},{"key":"2016102519281274000_19.10.pyw030.94","doi-asserted-by":"crossref","unstructured":"Marques TR Natesan S Niccolini F Politis M Gunn RN Searle GE Howes O Rabiner EA Kapur S (2016) Phosphodiesterase 10A in schizophrenia: a PET study using [C]IMA107. Am J Psychiatry. Advance online publication. doi: appiajp201515040518.","DOI":"10.1176\/appi.ajp.2015.15040518"},{"key":"2016102519281274000_19.10.pyw030.95","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr148"},{"key":"2016102519281274000_19.10.pyw030.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.10.009"},{"key":"2016102519281274000_19.10.pyw030.97","doi-asserted-by":"publisher","DOI":"10.1038\/35085068"},{"key":"2016102519281274000_19.10.pyw030.98","doi-asserted-by":"crossref","unstructured":"McCahill AC Huston E Li X Houslay MD (2008) PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. Handb Exp Pharmacol:125\u2013166.","DOI":"10.1007\/978-3-540-72843-6_6"},{"key":"2016102519281274000_19.10.pyw030.99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2011.00021","article-title":"Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions","volume":"5","author":"Medina","year":"2011","journal-title":"Front Neurosci"},{"key":"2016102519281274000_19.10.pyw030.100","doi-asserted-by":"crossref","first-page":"e00057","DOI":"10.1002\/prp2.57","article-title":"PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways","volume":"2","author":"Megens","year":"2014","journal-title":"Pharmacol Res Perspect"},{"key":"2016102519281274000_19.10.pyw030.101","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.211904"},{"key":"2016102519281274000_19.10.pyw030.102","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"2016102519281274000_19.10.pyw030.103","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.9.1415"},{"key":"2016102519281274000_19.10.pyw030.104","doi-asserted-by":"publisher","DOI":"10.1126\/science.1112915"},{"key":"2016102519281274000_19.10.pyw030.105","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2738"},{"key":"2016102519281274000_19.10.pyw030.106","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(99)00463-2"},{"key":"2016102519281274000_19.10.pyw030.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.11.056"},{"key":"2016102519281274000_19.10.pyw030.108","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000200178.34179.93"},{"key":"2016102519281274000_19.10.pyw030.109","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1493-07.2007"},{"key":"2016102519281274000_19.10.pyw030.110","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000215576.27615.fd"},{"key":"2016102519281274000_19.10.pyw030.111","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv219"},{"key":"2016102519281274000_19.10.pyw030.112","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv214"},{"key":"2016102519281274000_19.10.pyw030.113","doi-asserted-by":"publisher","DOI":"10.1515\/REVNEURO.1993.4.2.213"},{"key":"2016102519281274000_19.10.pyw030.114","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2011.00043"},{"key":"2016102519281274000_19.10.pyw030.115","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2518-08.2008"},{"key":"2016102519281274000_19.10.pyw030.116","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.10R01FM"},{"key":"2016102519281274000_19.10.pyw030.117","doi-asserted-by":"publisher","DOI":"10.1126\/science.1056784"},{"key":"2016102519281274000_19.10.pyw030.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.05.024"},{"key":"2016102519281274000_19.10.pyw030.119","unstructured":"Omeros (2014) Oremos provides update on PDE10 inhibitor program. Available at http:\/\/investor.omeros.com\/phoenix.zhtml?c=219263&p=irol-newsArticle_Print&ID=1979683."},{"key":"2016102519281274000_19.10.pyw030.120","unstructured":"Outsourcing Pharma (2014) PDE4 re-emerges as depression therapy. Available at http:\/\/www.outsourcing-pharma.com\/Preclinical-Research\/PDE4-re-emerges-as-depression-therapy."},{"key":"2016102519281274000_19.10.pyw030.121","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1238-14.2015"},{"key":"2016102519281274000_19.10.pyw030.122","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199902250-00021"},{"key":"2016102519281274000_19.10.pyw030.123","first-page":"563","article-title":"Rolipram in Parkinson\u2019s disease","volume":"40","author":"Parkes","year":"1984","journal-title":"Adv Neurol"},{"key":"2016102519281274000_19.10.pyw030.124","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-0618(00)00097-1"},{"key":"2016102519281274000_19.10.pyw030.125","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.08.026"},{"key":"2016102519281274000_19.10.pyw030.126","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.11.030"},{"key":"2016102519281274000_19.10.pyw030.127","doi-asserted-by":"crossref","unstructured":"Prickaerts J (2015) Phosphodiesterase inhibitors. In: Encyclopedia of psychopharmacology ( Stolerman I , ed), pp1306\u20131315. Berlin, Heidelberg: Springer.","DOI":"10.1007\/978-3-642-36172-2_403"},{"key":"2016102519281274000_19.10.pyw030.128","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00694-9"},{"key":"2016102519281274000_19.10.pyw030.129"},{"key":"2016102519281274000_19.10.pyw030.130","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.818656"},{"key":"2016102519281274000_19.10.pyw030.131","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2005.03937.x"},{"key":"2016102519281274000_19.10.pyw030.132","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2013.01.071"},{"key":"2016102519281274000_19.10.pyw030.133","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9814"},{"key":"2016102519281274000_19.10.pyw030.134","first-page":"467","article-title":"A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP","volume":"1224","author":"Rubin","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"2016102519281274000_19.10.pyw030.135","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002391"},{"key":"2016102519281274000_19.10.pyw030.136","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.595769"},{"key":"2016102519281274000_19.10.pyw030.137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06349.x"},{"key":"2016102519281274000_19.10.pyw030.138","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.03.020"},{"key":"2016102519281274000_19.10.pyw030.139","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001667"},{"key":"2016102519281274000_19.10.pyw030.140","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.02.002"},{"key":"2016102519281274000_19.10.pyw030.141","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2010.07080.x"},{"key":"2016102519281274000_19.10.pyw030.142","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03566.x"},{"key":"2016102519281274000_19.10.pyw030.143","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.05152.x"},{"key":"2016102519281274000_19.10.pyw030.144","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0852-07.2007"},{"key":"2016102519281274000_19.10.pyw030.145","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.132910"},{"key":"2016102519281274000_19.10.pyw030.146","doi-asserted-by":"publisher","DOI":"10.1007\/BF00586712"},{"key":"2016102519281274000_19.10.pyw030.147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.11.009"},{"key":"2016102519281274000_19.10.pyw030.148","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199505300-00009"},{"key":"2016102519281274000_19.10.pyw030.149","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(08)60573-5"},{"key":"2016102519281274000_19.10.pyw030.150","doi-asserted-by":"publisher","DOI":"10.2165\/0023210-200822120-00002"},{"key":"2016102519281274000_19.10.pyw030.151","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2006.04.013"},{"key":"2016102519281274000_19.10.pyw030.152","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.04.009"},{"key":"2016102519281274000_19.10.pyw030.153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311783110"},{"key":"2016102519281274000_19.10.pyw030.154","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06004.x"},{"key":"2016102519281274000_19.10.pyw030.155","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.230698"},{"key":"2016102519281274000_19.10.pyw030.156","doi-asserted-by":"publisher","DOI":"10.1042\/BST20110655"},{"key":"2016102519281274000_19.10.pyw030.157","doi-asserted-by":"publisher","DOI":"10.1042\/bse0330105"},{"key":"2016102519281274000_19.10.pyw030.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.09.008"},{"key":"2016102519281274000_19.10.pyw030.159","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.05.072"},{"key":"2016102519281274000_19.10.pyw030.160","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.08.051"},{"key":"2016102519281274000_19.10.pyw030.161","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2007.03.008"},{"key":"2016102519281274000_19.10.pyw030.162","doi-asserted-by":"crossref","unstructured":"Suzuki K Harada A Suzuki H Miyamoto M Kimura H (2016) TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms. Neuropsychopharmacology. Advance online publication. doi: 10.1038\/npp.2016.20.","DOI":"10.1038\/npp.2016.20"},{"key":"2016102519281274000_19.10.pyw030.163","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.44.101802.121415"},{"key":"2016102519281274000_19.10.pyw030.164","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.146332"},{"key":"2016102519281274000_19.10.pyw030.165","doi-asserted-by":"publisher","DOI":"10.1016\/j.baga.2013.08.001"},{"key":"2016102519281274000_19.10.pyw030.166","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.1.89"},{"key":"2016102519281274000_19.10.pyw030.167","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"2016102519281274000_19.10.pyw030.168","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.schres.2010.02.927","article-title":"Enhancement of cognition in schizophrenia via inhibition of phosphodiesterase-1B and potentiation of dopamine D1 receptor signaling","volume":"117","author":"Wennogle","year":"2010","journal-title":"Schizophrenia Res"},{"key":"2016102519281274000_19.10.pyw030.169","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2011.00055"},{"key":"2016102519281274000_19.10.pyw030.170","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.217026"},{"key":"2016102519281274000_19.10.pyw030.171","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/1381612820666140826114744","article-title":"Emerging biology of PDE10A","volume":"21","author":"Wilson","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2016102519281274000_19.10.pyw030.172","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-931498"},{"key":"2016102519281274000_19.10.pyw030.173","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2004.08.002"},{"key":"2016102519281274000_19.10.pyw030.174","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2005.12.042"},{"key":"2016102519281274000_19.10.pyw030.175","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.75.155"},{"key":"2016102519281274000_19.10.pyw030.176","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.75.91"},{"key":"2016102519281274000_19.10.pyw030.177","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.02.010"},{"key":"2016102519281274000_19.10.pyw030.178","doi-asserted-by":"publisher","DOI":"10.1038\/71345"},{"key":"2016102519281274000_19.10.pyw030.179","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1017435"},{"key":"2016102519281274000_19.10.pyw030.180","first-page":"166","article-title":"Phosphodiesterase targets for cognitive dysfunction and schizophrenia--a New York Academy of Sciences Meeting","volume":"13","author":"Zhang","year":"2010","journal-title":"IDrugs"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/19\/10\/pyw030\/7548788\/pyw030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T06:11:57Z","timestamp":1567750317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article-lookup\/doi\/10.1093\/ijnp\/pyw030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,2]]},"references-count":180,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,25]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1093\/ijnp\/pyw030"],"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyw030","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,2]]}}}